Pretax income is the income that a company earns before paying income taxes. Genprex's pretax income for the
three
months ended in Sep. 2024 was $-4.32 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-22.71 Mil.
Genprex's pretax margin was %.
Genprex Pre-Tax Income Historical Data
The historical data trend for Genprex's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genprex's Pre-Tax Income
For the Biotechnology subindustry, Genprex's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genprex's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genprex's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Genprex's Pre-Tax Income falls into.
Genprex Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Genprex's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genprex (NAS:GNPX) Pre-Tax Income Explanation
Genprex's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genprex Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Genprex's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GNPX has been successfully added to your 